Theralase Technologies Inc. designs, develops, manufactures and markets patented, superpulsed laser technology utilized in biostimulation and biodestruction applications. The technology is safe and effective in the treatment of chronic pain, neural muscular-skeletal conditions and wound care. When combined with its patented, light-sensitive Photo Dynamic Compounds, Theralase laser technology is able to specifically target and destroy cancers, bacteria and viruses. Theralase lasers are FDA, Health Canada and CSA/UL approved, and have international ISO 13485 certification.
Theralase's strategy includes two parts: production, marketing and distribution of the Theralase super-pulsed laser for sale to health-care practitioners (focusing on the treatment of chronic pain, sports injuries and wounds); and commercialization of (i) patented cancer treatment through progressive research, clinical trials and advancement of new technology in the direct destruction of cancers and (ii) destruction of bacteria and viruses through research utilizing patented, light-sensitive Photo Dynamic Compounds
Photodynamic therapy (PDT) is a potential treatment regime for a number of conditions. It involves introducing particular light-sensitive chemical species into biological systems, inducing them to localize at the point of interest, and then irradiating them with a light source.
It holds particular promise as a treatment to combat certain cancers, and the latest results from trials using a system developed by Ontario-based Theralase have shown that PDT was able to completely destroy subcutaneous colon cancer tumors in a mouse model. Four weeks after treatment, the mice remained free of cancer.